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paal.methlie@med.uib.noAbstractObjective: Liquid chromatography–tandem mass spectrometry (LC–MS/MS) offers superior
analytical specificity compared with immunoassays, but it is not available in many regions
and hospitals due to expensive instrumentation and tedious sample preparation.
Thus, we developed an automated, high-throughput LC–MS/MS assay for simultaneous
quantification of ten endogenous and synthetic steroids targeting diseases of the
hypothalamic–pituitary–adrenal axis and gonads.
Methods: Deuterated internal standards were added to 85 ml serum and processed by
liquid–liquid extraction. Cortisol, cortisone, prednisolone, prednisone, 11-deoxycortisol,
dexamethasone, testosterone, androstenedione and progesterone were resolved by
ultra-high-pressure chromatography on a reversed-phase column in 6.1 min and detected by
triple-quadrupole mass spectrometry. The method was used to assess steroid profiles in
women with Addison’s disease (AD, nZ156) and blood donors (BDs, nZ102).
Results: Precisions ranged from 4.5 to 10.1% relative standard deviations (RSD), accuracies
from 95 to 108% and extraction recoveries from 60 to 84%. The method was practically free
of matrix effects and robust to individual differences in serum composition. Most
postmenopausal AD women had extremely low androstenedione concentrations, below
0.14 nmol/l, and median testosterone concentrations of 0.15 nmol/l (interquartile range
0.00–0.41), considerably lower than those of postmenopausal BDs (1.28 nmol/l (0.96–1.64)
and 0.65 nmol/l (0.56–1.10) respectively). AD women in fertile years had androstenedione
concentrations of 1.18 nmol/l (0.71–1.76) and testosterone concentrations of 0.44 nmol/l
(0.22–0.63), approximately half of those found in BDs of corresponding age.
Conclusion: This LC–MS/MS assay provides highly sensitive and specific assessments of
glucocorticoids and androgens with low sample volumes and is suitable for endocrine
laboratories and research. Its utility has been demonstrated in a large cohort of women
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2–12 2 :126IntroductionGlucocorticoid and androgen hormone measurements
play a decisive role in the diagnosis and management of
many disorders of the hypothalamic–pituitary–adrenal
(HPA) axis and gonads. Examples include Addison’s
disease (AD), Cushing’s syndrome (CS) and congenital
adrenal hyperplasia, male hypogonadism and female
hyperandrogenism. Although immunoassays have largely
been used to measure steroid hormones, over the last
decade, mass spectrometry (MS) has increasingly been
adopted as it offers superior analytical specificity and
accuracy. However, MS is not commonly available to
clinicians in many regions and hospitals. The high cost of
MS instruments, lack of expertise, and cumbersome and
time-consuming sample preparation procedures are
factors likely to slow its adoption. The development of
simple, reliable, and cost- and labour-efficient methods is,
therefore, important.
Liquid chromatography coupled to tandem mass
spectrometry (LC–MS/MS) is a highly selective mode of
detection. It enables simultaneous determination of
multiple steroids at very low concentrations in a single
analytical run. Although many papers have been pub-
lished on LC–MS/MS assays that measure one or a few
steroid hormones, only few papers have reported methods
that extensively exploit the capability of multiplex
determination of steroids in human serum (1, 2, 3). This
strategy could simplify the laboratory set-up by eliminat-
ing the need to use numerous separate methods and make
instrument utilization more efficient.
In MS/MS, the specificity is increased by collision-
induced fragmentation of the analyte into a molecular
fingerprint that could be identified by monitoring two or
more fragments. However, many previously published
multisteroid LC–MS/MS assays monitor only one mass
transition (collision fragment) per analyte (2, 3, 4, 5, 6)
and consequently have an increased risk of not detecting
isobaric interference. Another analytical concern is that
inter-individual differences in serum composition, such as
lipids and binding proteins, could potentially impact
measurements. This is often not investigated at all. Most
published methods also require relatively large sample
volumes to provide sufficient sensitivity (1, 2, 4, 7, 8) and
have long run times (1, 2, 4, 7).
The work-up and management of endocrine disorders
commonly involve the administration of synthetic steroid
hormones. The determination of synthetic glucocorti-
coids used in dynamic endocrine testing and pharma-
cological treatment may thus be a valuable supplement tohttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdthe measurement of endogenous steroids. For example,
the measurements of serum dexamethasone (DXM)
could provide pharmacokinetic data useful in the
evaluation of the DXM suppression test (9, 10), and
therapeutic drug monitoring of prednisone and predniso-
lone has the potential to optimize treatment (11, 12).
Because of the widespread use of these glucocorticoids and
impact on endogenous cortisol levels, information on
serum levels may also be valuable in the setting of a
routine endocrine laboratory.
Therefore, the objective of this study was to develop a
LC–MS/MS method that quantifies endogenous and
synthetic glucocorticoid hormones as well as endogenous
androgens. With a sample volume of only 85 ml serum, the
method provides a highly sensitive, fast, comprehensive
and cost-effective evaluation of patients with a range of
disorders related to glucocorticoid and androgen hor-
mones. Its utility was demonstrated by comparing the
steroid profiles of women with AD with those of healthy
female blood donors (BDs). To our knowledge, this report
is the first to investigate androgen levels in a large cohort
of women with AD using highly specific MS.Materials and methods
Chemicals
Cortisol, cortisone, prednisolone, prednisone, 11-deoxy-
cortisol (11DOC), testosterone, androstenedione,
17a-hydroxyprogesterone (17OHP) and progesterone were
obtained from Steraloids, Inc. (Newport,RI, USA), and DXM
was obtained from Alfa Aesar (Ward Hill, MA, USA).
The deuterated internal standards (ISs) cortisol-d4
(cortisol-9,11,12,12-d4, 97–98% atom D), cortisone-d2
(4-pregnen-17a,21-diol-3,11,20-trione-1,2-d2, O98% atom
D), prednisolone-d6 (1,4-pregnadien-11b,17a,21-triol-3,
20-dione-2,4,6,6,21,21-d6, O98% atom D), DXM-d4
(DXM-4,6a,21,21-d4, 96–98% atom D), 11DOC-d2
(4-pregnen-17a,21-diol-3,20-dione-21,21-d2, O96% atom
D), testosterone-d3 (testosterone-16,16,17-d3, O98% atom
D), androstenedione-d7 (4-androsten-3,17-dione-2,2,4,6,6,
16,16-d7, O98% atom D), 17OHP-d8 (4-pregnen-17a-ol-3,
20-dione-2,2,4,6,6,21,21,21-d8, O98% atom D) and
progesterone-d9 (progesterone-2-2-4-6-6-17a,21,21,21-d9,
O98% atom D) were purchased from CDN Isotopes
(Pointe-Claire, Quebec, Canada).
MS-grade acetonitrile (ACN), methanol (MeOH),
formic acid (O98%) and ammonium formate (O98%)
were obtained from Merck. Milli-Q water purificationThis work is licensed under a Creative Commons
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3–12 2 :127system (Millipore, Burlington, MA, USA) was used to
prepare de-ionized water (O18 MUcm). Dextran-coated
charcoal (product number C6241) was obtained from
Sigma–Aldrich.
Calibrators, ISs and quality controls
Steroid-free human serum was prepared with activated
dextran-coated charcoal according to the manufacturer’s
protocol. Serum was obtained from healthy BDs.
All steroid hormones were separately dissolved in
MeOH at concentrations of 3 mM for the analytes and
500 mM for the ISs. Two separate mixtures of the analytes
and the ISs, designated standard substock and IS substock,
were prepared in MeOH. The standard substock contained
each steroid hormone at a concentration 100 times that of
the highest working calibrator. Working calibrators were
prepared by serially diluting the standard substock 1:4 in
MeOH and then by adding 2 ml of each dilution to 198 ml
steroid-free serum. The final working calibrators covered
the following measuring ranges: 1.95–2000 nmol/l, corti-
sol; 0.98–250 nmol/l, cortisone; 0.98–1000 nmol/l, pre-
dnisolone; 0.98–1000 nmol/l, prednisone; 0.06–250 nmol/l,
DXM; 0.10–25 nmol/l, 11DOC; 0.02–75.0 nmol/l,
testosterone; 0.12–125 nmol/l, androstenedione;
0.24–250 nmol/l, 17OHP; 0.24–250 nmol/l, progesterone;
and a blank control. Six calibrators were used for all the
analytes, except for cortisone and 11DOC (five calibrators)
and testosterone and DXM (seven calibrators).
The concentrations of each of the ISs in the IS substock
were 100 times that of the working IS solution. The
working IS solution was prepared by diluting the IS
substock with H2O:MeOH (1:1). The final working IS
solution contained 850 nmol/l cortisol-d4, 850 nmol/l
cortisone-d2, 425 nmol/l prednisolone-d6, 106 nmol/l
DXM-d4, 128 nmol/l 11DOC-d2, 51.0 nmol/l androstene-
dione-d7, 31.9 nmol/l testosterone-d3, 106 nmol/l
17OHP-d8 and 106 nmol/l progesterone-d9.
Quality controls (QCs) were prepared in steroid-free
serum at three levels (low, medium and high) by adding
each steroid hormone to a final concentration correspond-
ing to 0.30, 5.0 and 50% of the highest working standard.
All standards, calibrators and QCs were stored in Nunc
cryovials (Nalge Nunc International, Roskilde, Denmark)
at K80 8C.
Sample preparation procedure
To 85 ml of serum, working calibrators or QCs, 10 ml of an IS
were added, mixed and equilibrated for 1 h. The steroid
hormones were then extracted with 825 ml ethyl acetate:http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdhexane (80:20). The supernatant (600 ml) was transferred
to a new vial and washed with 50 ml ammonium formate
buffer (pH 9.0, 0.1 M). Subsequently, 500 ml of organic
phase were transferred to a new vial and evaporated at
50 8C for 25 min under N2 flow and finally reconstituted in
50 ml H2O:formic acid:MeOH (49.9:0.1:50). Sample prep-
aration was automated on a Hamilton Star (Hamilton
Robotics, Inc., Reno, NV, USA) using exclusively 1.1 ml
glass vials. Mixing steps were performed by repeated
pipette aspiration/dispense cycles. Centrifugation was
not necessary because the aquatic and organic phases
separated within minutes.LC–MS/MS conditions
An Agilent 1290 UPLC system (Santa Clara, CA, USA)
equipped with a thermostated autosampler (4 8C) and a
degasser was used for chromatographic separation. Pro-
cessed serum (5 ml) was separated over a Zorbax RRHD C18
reversed-phase column (50!2.1 mm, 1.8 mm particle
size, Agilent) maintained at 30 8C. The mobile phases
were water (A) and ACN (B) with 0.1% formic acid. The
column was developed with stepwise linear gradient
elution according to the following timetable: 0.00 min,
15% B; 0.25 min, 15% B; 0.50 min, 25% B; 1.70 min, 28.5% B;
3.80 min,40%B;4.20 min,50%B;4.90 min,70%B; 5.00 min,
95% B; 5.50 min, 95% B; 5.60 min, 15% B; and 6.10 min,
15% B. Flow rate was 1000 ml/min and the column effluent
was delivered to the mass spectrometer in the time
window 1.1–5.0 min.
The LC system was coupled to an Applied Biosys-
tems/MDS SCIEX API 5500 triple-quadrupole mass spec-
trometer operating with electrospray ionization (Applied
Biosystems/MDS, Foster City, CA, USA). Manual tuning
and selection of mass transitions were performed using a
T-split to mix the 5 ml/min infusion containing 500 nmol/l
of the compound with the 1000 ml/min mobile phase flow
(35% B). Using this set-up, additional Q1 and Q3 scans
(90–500 m/z) were performed by varying the ion source
parameters (voltage, temperature and gas flows) to
investigate the stability of the substances under conserva-
tive and extreme conditions, as well as the formation of
adducts. Ion source parameters and mass transitions are
reported in Table 1. Entrance potential was 10 V, collision
gas was set to medium and resolution was set to unit for
Q1 and Q3. To increase scan time for each analyte, the
multiple reaction monitoring (MRM) was divided into
seven periods based on the time of elution. All hardware
was managed using the Analyst Software (version 1.5.1;
Applied Biosystems/MDS).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.





time DP CE CXP MRM transition
Dwell
time DP CE CXP
Q1 Q3 (ms) (V) (V) (V) Q1 Q3 (ms) (V) (V) (V)
1
Cortisol 407.2 297.0 35 K50 K42 K23 407.2 282.0 10 K50 K49 K23
Cortisol-d4 411.4 301.1 35 K50 K45 K23 411.4 286.1 10 K50 K48 K23
Prednisolone 405.2 295.0 35 K50 K42 K23 405.2 280.0 10 K50 K48 K23
Prednisolone-d6 411.3 333.2 35 K50 K23 K23 411.3 284.1 10 K50 K48 K23
Prednisone 403.3 299.1 35 K50 K25 K23 403.3 285.1 10 K50 K40 K23
Cortisone 405.3 301.1 35 K50 K26 K23 405.3 311.1 10 K50 K41 K23
Cortisone-d2 407.3 303.1 35 K50 K28 K23 407.3 313.0 10 K50 K41 K23
2
DXM 437.4 361.1 80 K80 K24 K24 437.4 307.1 80 K80 K42 K15
DXM-d4 441.3 309.0 80 K80 K42 K20 441.3 363.2 80 K80 K24 K24
3
11DOC 347.2 96.9 80 50 30 12 347.1 108.9 80 50 31 12
11DOC-d2 349.3 108.9 80 50 33 12 349.3 96.9 80 50 30 12
4
Testosterone 289.2 97.0 80 85 30 12 289.2 109.0 80 85 33 12
Testosterone-d3 292.2 109.0 80 91 35 12 292.2 97.0 80 91 33 12
5
Androstenedione 287.2 96.9 60 105 30 16 287.2 108.9 60 105 33 15
Androstenedione-d7 294.1 99.7 60 116 29 16 294.1 113.0 60 116 35 15
6
17OHP 331.3 96.9 60 88 30 10 331.3 108.9 60 88 34 14
17OHP-d8 339.2 100.0 60 106 33 16 339.2 113.1 60 106 41 12
7
Progesterone 315.3 96.9 35 95 30 12 315.3 108.9 35 95 28 12
Progesterone-d9 324.2 100.2 35 110 37 12 324.2 113.0 35 110 27 12
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4–12 2 :128Quantification and QC
Quantification was based on peak area ratios of the analyte
to the corresponding IS. Standard curves were computed
using a linear least-squares regression analysis with 1/x or
1/x2 weighting to assign priority to the lower range of the
calibration curves.
To accept analytical runs, the back-calculated
concentrations of at least 80% of the working calibra-
tors had to be within G15% (20% for the lowesthttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdcalibrator) of their nominal concentration. Two sets of
QCs (low, medium and high) were run in each batch
(96 samples). The measured concentrations of at least
one QC at each level and at least 75% of all the QCs
were required to be within G15% their nominal levels.
Interference was suspected if the peak area ratio of
quantifier to qualifier transitions deviated more
than G40% from the corresponding ratio of the third
highest calibrator.This work is licensed under a Creative Commons
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5–12 2 :129Method validation
Within-day and between-day precisions were investigated
at three levels by running the QCs in replicates (nZ6) on
12 different days. The coefficients of variance (CV) were
calculated using one-way ANOVA. Accuracy (%) was
computed as (measured concentration/nominal concen-
tration)!100, using the means of all the measured
concentrations. The method was also compared with
immunoassays using the Passing–Bablok regression and
Bland–Altman plots.
The limits of detection (LoDs) and lower limits of
quantification (LLoQs) were determined by adding the
analytes at progressively lower levels to steroid-free serum
and analysing samples in replicates (nZ6). The LoD was
defined as the concentration with a signal-to-noise ratio
above 3 and the LLoQ as the lowest concentration with a
CV below 20% and accuracy within G20%.
Recovery, matrix effects (MEs) and linearity were
investigated in charcoal-stripped serum obtained from
different individuals, adopting the principles suggested by
Matuszewski et al. (13). Analytes were added to steroid-free
serum obtained from six individuals; aliquots of each
serum were spiked to six levels corresponding to the
working standards. Duplicate sera were spiked both before
extraction (pre-extract spike) and after evaporation (post-
extract spike) by adding 20 ml of the standard substock per
980 ml serum. Moreover, analytes were added to a ‘blank’
reconstitution solvent (reference). Reference samples were
analysed immediately before, in the middle and after the
pre/post-spike series. Extraction recoveries (ERs), ion-
source-related MEs and overall process efficiency (PE)
were calculated from the mean of duplicate samples
according to the formulas given in Supplementary
Table 1, see section on supplementary data given at the
end of this article. Evaporation of the organic phase during
sample preparation was closely monitored by gravimetric
measurements of simultaneously run control samples, and
ERs, MEs and PE were adjusted accordingly.
Linearity was evaluated based on residual plots
and correlation coefficients. Relative MEs (14), that is,
the impact of inter-individual differences in serum
composition, were assessed by computing the slope
constant based on each of the six pre-extraction spiked
sera from the recovery experiment. The slope constants
were derived from weighted (1/x or 1/x2) least-squares
linear regression of nominal concentration vs analyte:IS
peak area ratio.
All analytes and ISs and other potentially interfering
steroid hormones (Supplementary Table 2, see section onhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdsupplementary data given at the end of this article) were
prepared separately in water at concentrations of
2000 nmol/l. These included all drugs containing steroid
hormones that are commercially available in Norway. We
also reviewed data from random samples received at the
Hormone Laboratory (nZ926), from rheumatic patients
on prednisolone therapy (nZ50) and from patients taking
DXM (nZ25) for interfering peaks and deviations of the
quantifier:qualifier peak area ratio.
Stability was investigated by computing the mean of
triplet analysis of QCs at three concentration levels after
storage under different conditions. Stability was examined
after storage at ambient temperature for 1, 2, 4, 8, 24 and
96 h, in a refrigerator (4 8C) for 1, 2, 5, 10, 20 and 30 days,
and in a freezer (K20 8C) for 1, 2 and 3 months. Freeze–
thaw stability was determined after five cycles of freezing
to K80 8C. The stability of the processed samples (nZ96)
in the autosampler was studied by repeatedly analysing
the same batch on 4 consecutive days.Application: steroid profiles of women with AD and BDs
The method was applied to samples obtained from the
Norwegian registry of organ-specific autoimmune
diseases. The study population has been described
previously (15), and sera obtained from women with AD
(nZ156) and female BDs (nZ102) were analysed. The
Regional Committee for Medical Ethics of Western Nor-
way and the National Data Inspectorate approved the
study. All of the patients gave written informed consent
after complete explanation of the purpose and nature of
all the procedures used. Most of the AD patients were on
cortisone acetate replacement therapy, but five were using
prednisolone. Ten patients had premature ovarian failure
and seven were on DHEA replacement therapy. Blood
samples were drawn between 0800 and 1600 h. For
statistical analyses, the subjects were stratified into three
groups: young (!40 years), middle aged (40–60 years) and
old (O60 years). The groups were compared by the
Kruskal–Wallis test using the Wilcoxon test as a post hoc
analysis, and Bonferroni-adjusted P values are reported.
P!0.05 was considered statistically significant.Results
Precision, accuracy, lower limit of detection
and quantification
Data from the precision and accuracy experiments are
reported in Table 2. Total CV were %10.1% for all theThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 2 Precision and accuracy.






Mean 5.80 3.01 2.96 3.05 0.747 0.305 0.223 0.372 0.757 0.736
Within-day CV (%) 5.8 6.8 7.7 7.2 4.3 8.6 4.6 9.3 7.1 7.0
Total CV (%) 7.4 6.9 10.1 9.8 5.1 9.7 5.2 9.3 9.8 8.4
Accuracy (%) 97 100 99 102 100 102 99 99 101 98
QC 2
Mean 101 50.4 51.3 53.8 12.5 5.00 3.71 6.10 12.2 12.5
Within-day CV (%) 3.0 3.9 4.3 3.8 3.7 4.7 5.1 3.9 4.5 6.1
Total CV (%) 4.5 4.7 5.3 8.7 4.8 5.7 5.6 5.0 7.7 6.9
Accuracy (%) 101 101 103 108 100 100 99 98 98 100
QC 3
Mean 1004 – 517 535 128 – 36.4 61.6 121 118
Within-day CV (%) 4.7 – 5.0 4.7 4.0 – 4.7 4.1 4.6 4.5
Total CV (%) 5.7 – 5.5 8.8 5.2 – 4.9 5.0 8.0 6.8
Accuracy (%) 100 – 103 107 102 – 97 99 96 95
QCs were run in replicates of 6 on 12 different days. Total CV includes within-day and between-day variability. All concentrations are reported as nmol/l. QC 3
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6–12 2 :130compounds, and accuracies were in the range of 95–108%.
The LoDs and LLoQs are reported in Table 3, and
chromatograms of the lowest calibrators are shown in
Fig. 1. Comparison of the LC–MS/MS method with
immunoassays available in our laboratory is shown in Fig. 2.Recovery, linearity and MEs
Recovery and linearity were investigated in sera obtained
from six individuals (Supplementary Table 1). The ERs and
PE were high and consistent across low-to-high concen-
tration levels. The ER was 60% for progesterone, and it
ranged from 71 to 85% for the other analytes. There was
no significant ion depression or enhancement. The
method was linear for all the compounds, except for
cortisone and 11DOC. For these two compounds, the
highest calibrators of 250 and 25 nmol/l respectively were
slightly underestimated, but had acceptable back-calcu-
lated accuracies above 90%.
The variance of the slope constants between different
individuals provides a useful index of relative MEs. The CV
of the slope constants were %3% for all the analytes
(Supplementary Table 3, see section on supplementary
data given at the end of this article). According to
Matuszewski (14), this indicates that the method is robusthttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdto intra-individual differences in the serum. On running
routine samples, it was observed that the peak areas of the
ISs were consistent over a batch of 96 samples with CV
typically in the range of 10–20%.Selectivity
Potential analytical interference of 48 synthetic and
naturally occurring steroid hormones and metabolites
(Supplementary Table 2) was investigated. All the analytes
were chromatographically separated, except prednisone
and prednisolone. Individual injection of these two
compounds at 2000 nmol/l showed that the selected
fragment ions of these glucocorticoids did not interfere
in the negative ionization mode. In the systematic
evaluation of chromatograms from 1000 routine analyses,
suspicion of interference was very rare. The quantifier:
qualifier peak area ratio was within G40% of the expected
value for all the analytes of all the samples.Stability
Steroid hormones in the serum were stable when stored at
4 8C or a lower temperature. After storage for up to 25 days
at 4 8C or over 6 months at K20 8C, all the compoundsThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 3 Limits of detection (LoDs) and lower limits of quantification (LLoQs).





LoD (nmol/l) !0.1 !0.1 !0.2 !0.2 !0.03 !0.03 !0.01 !0.02 !0.06 !0.06
LoQ (nmol/l) 1.95 1.58 0.49 0.97 0.061 0.098 0.018 0.122 0.244 0.122
CV (%) 11.4 6.7 12.3 18.3 5.4 17.3 18.8 16.9 14.2 16.9
Accuracy (%) 94.6 117.9 86.0 103.6 112.0 103.5 116.2 103.8 95.9 113.4
LoD is defined as a signal-to-noise ratio above 3. LoQ is defined as the lowest level that could be measured with accuracy within G20% of the nominal levels
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7–12 2 :131were still measured within G10% of their nominal levels
with no apparent trends. The compounds were robust to at
least five freeze–thaw cycles. Cortisone concentrations
were within G10% of the nominal levels after 48 h of
storage at ambient temperature; however, for samples
containing levels of 50 nmol/, concentrations declined to
86% after 96 h. Similarly, at this time point, the
concentrations of samples with prednisone at an initial
level of 50 nmol/l had declined to 84%. Reconstituted
samples were stable for at least 4 days at 4 8C.Application: steroid profiles of women with AD and BDs
The steroid profiles of patients with AD and BDs are
reported in Table 4. The method provided information on
the cortisol and cortisone levels of patients on oral
hydrocortisone replacement therapy and successfully
identified the five patients taking prednisolone (predniso-
lone 317 nmol/l, range 220–419; prednisone 47.8 nmol/l,
range 17.2–86). Nine AD patients had low levels of 11DOC
(median 0.20; range 0.14–0.32 nmol/l).
Testosterone and androstenedione concentrations
were above the LLoQs in all the BDs and most of the
women with adrenal insufficiency. The two AD groups of
women aged above 60 years and women with premature
ovarian failure stood out as in them androgen levels were
often not even detectable. Generally, patients with AD
exhibited decreasing serum testosterone concentrations
with age, and levels were significantly lower in the old
group vs the young group (PZ0.0195). This was in
contrast to the testosterone levels in BDs, where no
difference between the old and young groups was observed
(PZ1). The middle-aged BDs, however, had lower levels
than the young group (PZ0.003).
Serum androstenedione concentrations also declined
with age in women with AD. Androstenedione concen-
trations in the old group were lower than those in thehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdmiddle-aged group (P!0.00001), which again were lower
than those of the young group (PZ0.006). For BDs,
androstenedione concentrations were not significantly
different in the middle-aged group and the old group
(PZ0.160). The young group had higher levels relative to
the middle-aged group (PZ0.0002) and the old group
(PZ0.00007).
On comparing women with AD with BDs, it was
found that testosterone levels were significantly lower in
all the age-stratified groups (all P%0.00020). Similarly,
androstenedione concentrations were lowest in AD
patients (all P%0.00005). The levels of 17OHP in the old
groups were lower in AD patients than in the BDs
(P!0.00001). There were no systematic differences in
serum cortisol and cortisone levels between AD patients
and BDs, as expected since the timing of specimen
collection was not standardized.Discussion
We developed a multiplexed LC–MS/MS assay that targets
the work-up of adrenal and gonadal disorders. As
demonstrated by the steroid profiles of women with AD,
it allows the quantification of very low levels of androgens,
as well as measurements of endogenous and synthetic
glucocorticoids. The method is automated, requires only
85 ml serum and has a chromatographic run time of
6.1 min, which makes it suitable for use in routine
endocrine laboratories as well as in research.
The panel of analytes includes the most commonly
systemically used synthetic glucocorticoids. This could be
particularly useful in a clinical setting as it enables a
comprehensive assessment of the patient. For example,
the overnight low-dose DXM suppression test is com-
monly used in the work-up of CS, but its diagnostic
specificity of only 80% is a major drawback (16). The
determination of serum DXM could help in identifyingThis work is licensed under a Creative Commons























































































































































MS chromatograms of the quantifier mass transition of the lowest working
calibrator for each analyte. The nominal concentrations were as follows:
1.95 nmol/l, cortisol; 0.98 nmol/l, cortisone; 0.98 nmol/l, prednisolone;
0.98 nmol/l, prednisone; 0.10 nmol/l, 11-deoxycortisol (11DOC);
0.06 nmol/l, dexamethasone (DXM); 0.02 nmol/l, testosterone; 0.12 nmol/l,
androstenedione; 0.24 nmol/l, 17a-OH-progesterone (17OHP); and
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8–12 2 :132patients with false-positive tests due to reduced gastro-
intestinal DXM absorption or abnormal DXM metab-
olism. This strategy is indeed suggested by the Endocrine
Society (17), but rarely implemented. Moreover, the
detection of synthetic glucocorticoid hormones could
reveal iatrogenic causes of CS as well as prevent unnecess-
ary investigations in patients with iatrogenic cortisol
suppression, both circumstances commonly encountered
in the routine laboratory. Moreover, prednisolone and
prednisone are commonly used as immunosuppressants
and in the treatment of cancer. It is a clinical observation
that these drugs show considerable inter-individual
variation in dose required for therapeutic effect. Analo-
gously, some patients are more resistant to adverse effects.
Therapeutic monitoring of prednisolone and prednisone
levels may ultimately optimize clinical response and
reduce adverse effects, such as osteoporosis and cardiovas-
cular disease (18, 19, 20).http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica LtdOur LC–MS/MS assay allows the quantification of
serum testosterone in the picomolar range found in
women and children, which traditional immunoassays
cannot measure reliably (21). We achieved a LLoQ for
testosterone of less than one-fifth of that reported by Guo
et al. (2) and Ceglarek et al. (3), and functional sensitivity
was similar to that of methods employing labour-intensive
derivatization procedures to enhance the ionization
of androgens (5, 8). The LLoQs in the range of
0.02–1.97 nmol/l are, for most of the analytes, lower
than those of previously published LC–MS/MS methods,
although our method requires less serum volume (1, 2, 3,
4, 5, 7, 8). Combined with simultaneous determination of
multiple hormones, low serum volume requirement is an
advantage when the specimen is scarce, such as samples
from children and population-based biobanks. The low
sample volume used also facilitates high-throughput
analysis by allowing unattended automation of theThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 2
Comparison of the LC–MS/MS method with immunoassays available at the
Hormone Laboratory. Statistical analyses were carried out using the
Passing–Bablok regression (upper) and Bland–Altman plots (lower).
Arrows in cortisol plots denote a patient put on prednisolone therapy in
whom the immunoassay reported falsely elevated cortisol levels
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9–12 2 :133extraction procedure in a standard 96-well format using a
liquid-handling robot. Within an 8-h workday, 288
samples can be prepared, and more than 200 samples per
day can be analysed.
When hormones with different chemical properties
are assayed simultaneously, there is a balance between
obtaining high recoveries for all the compounds and
eliminating substances that cause ion suppression or
impact method ruggedness. Overall, extraction with ethyl
acetate:hexane yielded high recoveries without significant
ion suppression or enhancement. The clean extractshttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdcontributed to the long lifetime of the analytical column,
which typically withstood thousands of injections.
Although MS is a highly specific analytical detector, it
is necessary to chromatographically separate the steroid
analytes from isobaric isomers and other interfering
compounds. We found that the Zorbax RRHD C18 column
performed well for both glucocorticoids and androgens.
A reversed-phase column with phenyl-bonded stationary
phase may better separate cortisol, cortisone, predniso-
lone and prednisone (22), but is incapable of resolving
androgens from interfering compounds. Because theThis work is licensed under a Creative Commons
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Published by Bioscientifica Ltdglucocorticoids formed specific adducts with formic acid
in the negative ionization mode, the co-elution of
prednisone and prednisolone was without significant
cross-interference.
The increasing sensitivity of the latest generation of MS
instruments has increased awareness and concern for
isobaric interferences, in particular, in the picomolar
range. Monitoring two mass transitions (i.e. collision
fragments) adds another layer of specificity as an unex-
pected deviation of the ratio of the quantifier to qualifier
peak areas should raise suspicion of interference (23, 24).
Although monitoring two mass transitions reduces scan
time and thus sensitivity and LLoQ, this strategy has been
recommended (25) or advised as mandatory (26) for steroid
analysis. Our assay monitors two mass transitions, which
we believe is an important improvement compared with
other multisteroid methods (2, 3, 4, 5, 6).
Inter-individualdifferences in serum composition could
potentially impact measurements. For example, the ER of
steroids in the serum may vary with the amount of binding
proteins and lipids. An isotopic analogue of the analyte is
commonly used as an IS to compensate for such loss.
Nevertheless, it is still possible that the binding of the IS to
various components in the serum is not in perfect
equilibrium with the analyte. Another concern, particularly
relevant to the increased resolution offered by ultra-high-
pressure LC, is that the ionization efficiency of the analyte
and IS may differ as they do not always co-elute exactly (27).
Therefore, a strength of our method is the comprehensive
validation of relative MEs, which often are not investigated
at all (1, 2). The consistent results obtained when calibration
curves were prepared for sera collected from different
individuals indicate that the assay is robust to inter-
individual differences in serum composition.
The clinical usefulness of the method was demon-
strated by comparing steroid profiles of women with AD
with those of BDs. The measurements of endogenous and
synthetic glucocorticoids indicate the potential of the
method to assess patients on glucocorticoid therapy. The
five patients on prednisolone replacement therapy were
identified by the detection and quantification of pre-
dnisone and prednisolone.
Herein, we report data on androgens in women with
AD. To our knowledge, this study is the first to investigate
testosterone and androstenedione concentrations in a
large cohort of women with adrenal insufficiency using
highly specific MS. To differentiate between premenopau-
sal and postmenopausal status, we stratified the study
subjects into young (!40 years), middle-aged (40–60
years) and old (O60 years) groups. The middle-agedThis work is licensed under a Creative Commons
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11–12 2 :135group is expected to comprise a mixture of fertile and
postmenopausal women. We found that in AD women
aged below 40 years, androstenedione and testosterone
concentrations were roughly 50% of those found in BDs.
This is in line with studies indicating that androgens
originate from the adrenal glands and ovaries at about
equal ratios in fertile healthy females (28). An interesting
finding is the very low androgen levels in women with AD
aged above 60 years, as opposed to the levels in healthy
females of comparable age. This may suggest that
postmenopausal women with AD, in particular, are
deficient of androgens. It also raises the question as to
why the postmenopausal ovary in AD ceases to secrete
androgens. Notably, there has long been a controversy
whether the postmenopausal ovary indeed is a major
androgen-producing organ (29, 30). A reasonable interpre-
tation of our data could be that the premenopausal ovary is
capable of de novo androgen synthesis, while the post-
menopausal ovary depends on adrenal DHEA/S as the
substrate to produce testosterone and androstenedione.
This would explain the low androgen levels found in
postmenopausal women with AD. Moreover, this may also
explain some of the discrepant results of DHEA replace-
ment in AD (15, 31, 32, 33) because the study populations
investigated differ in gender, menopausal status and
autoimmune ovarian failure. Conceivably, DHEA replace-
ment therapy may be more effective in the postmenopau-
sal AD women without autoimmune ovarian damage.
Alteration in binding globulin, for example, due to the
use of oral contraceptives, could potentially influence the
unbound levels of androgen in the serum. We did not
measure SHBG levels, which is a limitation of our study. If
SHBG levels were considerably lower in women with AD
than in the BDs, one would expect the free fractions levels in
AD to be increased relative to total hormone levels. However,
previous reports indicate that SHBG levels in adrenal failure
are in the middle-to-upper normal range, 65–90 nmol/l
(34, 35, 36). Moreover, the postmenopausal women in our
study were not on oral contraceptives. We, therefore, believe
that the very low levels of total serum testosterone and
androstenedione in women with AD indicate reduced
bioactive androgens available to target tissues.
In conclusion, we developed a simple, automated, fast
and highly specific LC–MS/MS assay that quantifies
endogenous androgens and glucocorticoids, together
with common synthetic glucocorticoids used in diagnosis
and treatment. The method is highly sensitive and allows
the measurement of androgens in women and children.
The abilities of the method were illustrated by profiling
steroid hormones in a large cohort of females with andhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0023
 2013 The authors
Published by Bioscientifica Ltdwithout AD. The levels of androgens were lowest in
women with AD across all age groups, but particularly in
those aged above 60 years. This may suggest that androgen
synthesis in the postmenopausal ovary depends on
adrenal DHEA/S as the substrate.
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This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-13-0023.
Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.
Funding
The study was supported by grants from The Regional Health Authorities of
Western Norway and the European Union (FP7 Euradrenal, grant no. 201167).
Acknowledgements
We thank Franziska Randers, Otto Borholm, Øyvind S Holen and
Ole-Thomas S Andersen for their excellent technical assistance and
interesting discussions.
References
1 Guo T,ChanM & Soldin SJ. Steroidprofilesusing liquidchromatography–
tandem mass spectrometry with atmospheric pressure photoionization
source. Archives of Pathology & Laboratory Medicine 2004 128 469–475.
2 Guo T, Taylor RL, Singh RJ & Soldin SJ. Simultaneous determination of
12 steroids by isotope dilution liquid chromatography–photospray
ionization tandem mass spectrometry. Clinica Chimica Acta 2006 372
76–82. (doi:10.1016/j.cca.2006.03.034)
3 Ceglarek U, Kortz L, Leichtle A, Fiedler GM, Kratzsch J & Thiery J. Rapid
quantification of steroid patterns in human serum by on-line solid
phase extraction combined with liquid chromatography–triple quad-
rupole linear ion trap mass spectrometry. Clinica Chimica Acta 2009 401
114–118. (doi:10.1016/j.cca.2008.11.022)
4 Harwood DT & Handelsman DJ. Development and validation of a
sensitive liquid chromatography–tandem mass spectrometry assay to
simultaneously measure androgens and estrogens in serum without
derivatization. Clinica Chimica Acta 2009 409 78–84. (doi:10.1016/
j.cca.2009.09.003)
5 Keski-Rahkonen P, Huhtinen K, Poutanen M & Auriola S. Fast and
sensitive liquid chromatography–mass spectrometry assay for seven
androgenic and progestagenic steroids in human serum. Journal of
Steroid Biochemistry and Molecular Biology 2011 127 396–404.
(doi:10.1016/j.jsbmb.2011.06.006)
6 Moal V, Mathieu E, Reynier P, Malthièry Y & Gallois Y. Low serum
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